Source Profiling of Biohazardous Aerosols in Hospitals
Completed
- Conditions
- Respiratory Tract Infections
- Registration Number
- NCT00517660
- Lead Sponsor
- Hospital Authority, Hong Kong
- Brief Summary
To characterise the physical parameters (number concentration, size distribution and their trajectories) of aerosols (droplets) generated in high risk procedures.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Adult patients (>18 years old) that can give valid consent
- URTI: with symptoms such as coryza, sore throat, nasal discharge, cough and sputum +/- fever. Amongst these, cough should be a major complaint.
- LRTI (CAP): acute lower respiratory illness of no other known cause which is usually associated with fever, symptoms and signs of the chest and abnormalities on the CXR. (BTS 1993).
Exclusion Criteria
- Pneumonia developed at or after 48 hours, or history of hospital admissions within 1 month of the present admission (to exclude hospital-acquired infections)
- Patients who are unable to cooperate with the study protocols (such as mentally confused, dementia) or are physically unable to sit or stand independently to carry out the tests optimally.
- Patients with TOCC associations with infections such Avian Flu or SARS (travel to endemic areas, at-risk occupations, close contacts with index cases, especially with compatible clinical features) or NPA revealed positivity of influenza A/B
- Patients who are clinically or haemodynamically unstable, such as the need for inotropes, oxygen supplement of >2L/min, any types of shock, etc.
- Underlying diseases that might affect the coughing effort (such as musculoskeletal diseases, or severe kyphoscoliosis)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the physical parameters of biohazardous aerosols in hospital settings during high-risk procedures for respiratory tract infections?
How do aerosol size distribution and trajectories impact transmission dynamics of respiratory pathogens in clinical environments?
What molecular mechanisms underlie aerosol generation in procedures linked to respiratory tract infections?
Are there biomarkers that correlate with aerosolization risk in patients with specific respiratory tract infection subtypes?
What are the comparative effectiveness and safety of aerosol containment strategies in hospitals versus standard-of-care infection control protocols?
Trial Locations
- Locations (1)
Queen Elizabeth Hospital
🇨🇳Hong Kong, China
Queen Elizabeth Hospital🇨🇳Hong Kong, China